You are here » Home » Companies » Company Overview » ABL Bio-Technologies Ltd

ABL Bio-Technologies Ltd.

BSE: 526955 Sector: Health care
NSE: N.A. ISIN Code: INE707D01016
BSE LIVE 12:05 | 11 Jul Stock Is Not Traded.
NSE LIVE 05:30 | 01 Jan Stock Is Not Traded.
OPEN 0.80
PREVIOUS CLOSE 0.78
VOLUME 37663
52-Week high 1.11
52-Week low 0.73
P/E
Mkt Cap.(Rs cr) 0.66
Buy Price 0.81
Buy Qty 2937.00
Sell Price 0.00
Sell Qty 0.00
OPEN 0.80
CLOSE 0.78
VOLUME 37663
52-Week high 1.11
52-Week low 0.73
P/E
Mkt Cap.(Rs cr) 0.66
Buy Price 0.81
Buy Qty 2937.00
Sell Price 0.00
Sell Qty 0.00

ABL Bio-Technologies Ltd. (ABLBIOTECH) - Company History

ABL Bio Technologies Limited (ABL) is an India-based biotechnology company. The Company operates in three segments: formulation, research and development and the Docosahexaenoic acid (DHA) project. The Company focuses on discovery, collection of microbes, establishment of compound libraries, discovery of drug and nutrition targets and conducting research and converting the strains/compounds in to deliverable active pharmaceutical products. ABL Biotechnologies was incorporated in the year 1992. ABL is engagaed in identification and commercial extraction of bio-chemicals, predominantly from microbes, that are used as nutritional, cosmetic, pharmaceutical, and industrial intermediates. Companys R&D unit is located at Vishakapatnam that has been recognised by the Department of Scientific and Industrial Research, Ministry of Science and Technology, Government of India. Companys microbial metabolites laboratory located at Chennai is focused on evaluating new sources of biochemicals from marine organisms. Company has collaborated with institutions such as the National Facility for Marine Cyanobacteria, Bharathidasan University, Trichy, the National Institute of Oceanography, The Madras University and the Dr.A.L.M Post Graduate Institute of Medical Sciences, Madras to introduce joint development programmes of advanced research in India. Company has taken various initiatives such as sale or licensing of technologies, development of biochemical intermediates, conducting research on aquatic biotechnology, product development for therapeutics industry and undertaking contract research. Under contract research company manufactures finished formulations in various formats including soft and hard gelatine capsules, tablets, liquid orals and topical ointments, for various disease states. ABL has been conducting research on polysaccharides, essential fatty acids, natural pigments, tracers and tags with considerable success. Presently company is focus on developing pharmaceuticals products catering various areas like anti-bacterials and anti-virals, enzymes, bio-molecular materials, bio-monitors and diagnostics, bio-pesticides, bioremediation and aquaculture. As of March 31, 2010, the Company is conducting research on multiple Active Pharmaceutical Ingredients (APIs).

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard